Van Nevel Retires as NCI Communications Chief

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 2
Volume 9
Issue 2

BETHESDA, Md-J. Paul Van Nevel ended a 26-year career at the National Cancer Institute on Dec. 31, when he retired as associate director for cancer communications. He immediately began a new career as a communications consultant, with NCI as a client.

BETHESDA, Md—J. Paul Van Nevel ended a 26-year career at the National Cancer Institute on Dec. 31, when he retired as associate director for cancer communications. He immediately began a new career as a communications consultant, with NCI as a client.

NCI director Richard D. Klausner, MD, praised Mr. Van Nevel at the National Cancer Advisory Board meeting and thanked him for his contributions to the Institute. Dr. Klausner noted that Mr. Van Nevel would “help us negotiate the transition to the post-Paul Van Nevel era at NCI.”

Mr. Van Nevel joined NCI as deputy director of communications in 1973, following 5 years in media relations at Johns Hopkins. He was named head of NCI’s communications office in 1974. Nelvis Castro, chief of NCI’s health promotion branch, will serve as acting associate director for cancer communications.

Recent Videos
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.